Abstract: A transposon (TnC_T7) was developed to partially supply the transcriptional machinery during functional analysis of genomic/metagenomic libraries. This transposon was conceived and constructed to have the ability to integrate randomly into any episomal DNA, allowing the inducible expression of the adjacent DNA regions in both directions. In general, this genetic tool included a kanamycin resistance gene, two bidirectional T7 promoters and the T7RNA polymerase-coding gene, the latter under the regulation of the inducible arabinose promoter (PBAD). The experimental validation confirmed the TnC_T7 potential to be used in functional genomic/metagenomic studies, in order to partially overcome the limitations of the bacterial hosts, which prevent them to recognize most of foreign genes from DNA libraries.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
October 26, 2021
Assignees:
UNIVERSIDAD DE LOS ANDES, CORPORACION CORPOGEN
Inventors:
Alvaro Mongui, Patricia Del Portillo Obando, Silvia Restrepo Restrepo, Armando Junca Howard
Abstract: This invention refers to the obtainment of a modified lipolytic enzyme that was isolated, expressed and purified from the heterologous expression. The gene sequence that codifies for the basal enzyme was obtained based on a thermo acidophilus organism of the acidobacteraceae family. This basal enzyme that comes from a thermo acidophilus organism, it is able to hydrolyze lipid substrates (triacylglycerols) united to middle chain fatty acids (C6-C10) such as tributyrine and tricapryln, among others. It also can carry out other inverse reactions to the hydrolysis such as synthesis reactions. On the other hand, this enzyme has enantioselective preference on (S) substrates of profens esters such as ibuprofen, naproxen and others. The enantioselective lipolytic basal enzyme was modified in its terminal C end to add an amino acid histidine tail that gives a higher efficiency in its purification process.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
September 3, 2019
Assignees:
CORPORACIÓN CORPOGEN, PONTIFICA UNIVERSIDAD JAVERIANA
Abstract: This invention refers to the obtainment of a modified lipolytic enzyme that was isolated, expressed and purified from the heterologous expression. The gene sequence that codifies for the basal enzyme was obtained based on a thermo acidophilus organism of the acidobacteraceae family. This basal enzyme that comes from a thermo acidophilus organism, it is able to hydrolyze lipid substrates (triacylglycerols) united to middle chain fatty acids (C6-C10) such as tributyrine and tricapryln, among others. It also can carry out other inverse reactions to the hydrolysis such as synthesis reactions. On the other hand, this enzyme has enantioselective preference on (S) substrates of profens esters such as ibuprofen, naproxen and others. The enantioselective lipolytic basal enzyme was modified in its terminal C end to add an amino acid histidine tail that gives a higher efficiency in its purification process.
Type:
Application
Filed:
April 30, 2015
Publication date:
May 11, 2017
Applicants:
CORPORACIÓN CORPOGEN, PONTIFICIA UNIVERSIDAD JAVERIANA